# A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C

Study · id `cardio:ct-nct06165250` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06165250](<https://clinicaltrials.gov/study/NCT06165250>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06165250

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

## Technical summary

Registry record NCT06165250. Randomized; double masking; primary purpose treatment. Start 2024-04-17 (actual); primary completion 2025-11-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 151 participants (enrolled count; ClinicalTrials.gov record NCT06165250, source copy `cardio:ctgov-nct06165250-2026-08-19`, retrieved 2026-10-26)
- Started: 2024-04-17 (actual) (ClinicalTrials.gov record NCT06165250, source copy `cardio:ctgov-nct06165250-2026-08-19`, retrieved 2026-10-26)
- Primary completion: 2025-11-11 (actual) (ClinicalTrials.gov record NCT06165250, source copy `cardio:ctgov-nct06165250-2026-08-19`, retrieved 2026-10-26)
- Completion: 2025-11-11 (actual) (ClinicalTrials.gov record NCT06165250, source copy `cardio:ctgov-nct06165250-2026-08-19`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06165250, source copy `cardio:ctgov-nct06165250-2026-08-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06165250-2026-08-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
- Condition: Essential Hypertension
- Condition: Primary Hypercholesterolemia
- Intervention (Drug): BR1018A
- Intervention (Drug): BR1018A-1
- Intervention (Drug): BR1018B
- Intervention (Drug): BR1018B-1
- Intervention (Drug): BR1018C
- Intervention (Drug): BR1018C-1
- Lead sponsor: Boryung Pharmaceutical Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Boryung Pharmaceutical Co., Ltd (`cardio:org-boryung-pharmaceutical-co-ltd`)

## Provenance

Content hash: 7f073b37fbfa0e4e1ca463d06d6067b01987a9b33288ccef2b94841b9b253b85
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
